Survodutide — Benefits, Dosage & Where to Buy

Research Overview

Survodutide is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Unlike pure GLP-1 agonists, survodutide also activates glucagon receptors, which increases hepatic energy expenditure, promotes fat oxidation, and reduces liver fat content. This dual mechanism provides weight loss benefits beyond appetite suppression alone. In phase 2 trials, survodutide demonstrated up to 19% body weight reduction at 46 weeks and significant improvements in liver fat and fibrosis markers in MASH patients. Phase 3 trials are ongoing.